39 DEVELOPED HCC by EASL criteria

Slides:



Advertisements
Similar presentations
High Resolution studies
Advertisements

Protein GP73 (GOLGI PROTEIN 73) A NEW NON-INVASIVE BIOMARKER FOR ASSESSING LIVER FIBROSIS AND RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA N.K. Gatselis,
Differences between radiology and histopathology: Are we judging correctly? Simona Onali 1, Emmanuel Tsochatzis 1, James O’Beirne 1, Aileen Marshall 1,
Skull Base Chordoma and Chondrosarcoma: Changes in National Radiotherapy Patterns and Survival Outcomes Henry S. Park, MD, MPH; Kenneth B. Roberts, MD;
INTRODUCTION Upper respiratory tract infections, including acute pharyngitis, are common in general practice. Although the most common cause of pharyngitis.
Evaluating Results of Learning Blaž Zupan
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Vitamin D: A New Frontier in Diabetes Management Contact Information: Background Acknowledgement Methods.
©2016 MFMER | slide-1 Patient screening tools associated with prediction of depression remission at six months Kurt B. Angstman, MS MD Professor of Family.
심 재 준심 재 준 Am J Gastroenterol 2007;102:
Golgi Protein-73 Shows Promise as a Sensitive Serum Marker for HCC Slideset on: Marrero J, Romano P, Nikolaeva O, et al. GP73, a resident golgi glycoprotein,
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
TACE for HCC in a regional centre: 5 year audit and assessment of baseline predictors of outcome Iain DS Morrison, #R Kasthuri, EH Forrest, S Barclay,
Vitamin D Inadequacy is Highly Prevalent Among North American Women Treated for Osteoporosis MF Holick1, ES Siris2, N Binkley3, MK Beard4, AA Khan5, JT.
Bootstrap and Model Validation
Texas Pediatric Society Electronic Poster Contest
Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.
External multicentric validation of a COPD detection questionnaire.
1University of Kentucky, Lexington, Kentucky
Yolk sac diameter as a predictor of pregnancy outcome
– р<0.05 between baseline
Figure 1. Onset of PIV catheter complications
Diabetes and Hypertension Health Screening in the Fresno Sikh Population: A Cross Sectional Approach Baljit Singh Dhesi 1,2 1University of California,
Leah Li MRC Centre of Epidemiology for Child Health
. Troponin limit of detection plus cardiac risk stratification scores for the exclusion of myocardial infarction and 30-day adverse cardiac events in ED.
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
When Using DOPPS Slides
* Potential use of HP and AMBP in urine for the screening of prostate cancer Sanja Kiprijanovska1, Selim Komina2, Gordana Petrusevska2,
Anastasiia Raievska (Veramed)
PLASMA HOMOCYSTEINE LEVELS AS A PREDICTOR
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.
Long-term impact of response to interferon-based therapy in patients with chronic HCV in relation to liver function, survival and cause of death Philip.
TBCRC (the translational breast cancer research consortium) 005 Prospective study
Diagnostic characteristics and prognoses of primary-care patients referred for clinical exercise testing: a prospective observational study Nilsson G1,
Effect of Acute Kidney Injury on Chronic Kidney Disease Progression and Proteinuria: Initial Results from a Pilot Study Horne K1, Scott R1, Packington.
Sammour T, Singh PP, Su’a B, Zargar-Shoshtari K, Hill AG
Evaluating Results of Learning
Interrater agreement and time it takes to assign a Canadian Triage and Acuity Scale score in 7 emergency departments McLeod, S.L.1,2 McCarron, J.3 Stein,
Vrushali Patwardhan, Dinesh Kumar, Varun Goel, Sarman Singh
Physical Activity Reductions in Male Veterans With Traumatic Brain Injury Karl F. Kozlowski 1,Greg Homish 1, Michelle Alt 2, Sarah Piwowarczyk 2, Kerry.
Integrated microRNA-mRNA profiling identifies molecular biomarkers in bladder outlet obstruction-induced lower urinary tract dysfunction Fiona C. Burkhard1,
Development and Validation of HealthImpactTM: An Incident Diabetes Prediction Model Based on Administrative Data Rozalina G. McCoy, M.D.1, Vijay S. Nori,
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Carrie O’Reilly, Ph.D., M.S.N., RN Touro University Nevada
The association between recent travel and risk of malaria: prospective cohort studies at 3 sites in Uganda with varied transmission intensity ASTMH 66th.
Surgeon intuition is inferior to a simple web-based risk calculator for predicting anastomotic leak. Tarik Sammour, Mark Lewis, Michelle L Thomas, Matt.
Acute Assessment of Mild Traumatic Brain Injury with the King-Devick Test in an Emergency Department Sample Objectives Results The MTBI and trauma control.
EVAAS Overview.
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
Antibody Concentrations Decrease 14-Fold in Children With Celiac Disease on a Gluten-Free Diet but Remain High at 3 Months  David Petroff, Johannes Wolf,
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients  Sarah Berhane, Hidenori.
JAMA Pediatrics Journal Club Slides: Association of Salivary MicroRNA Changes With Prolonged Concussion Symptoms Johnson JJ, Loeffert AC, Stokes J, et.
JAMA Pediatrics Journal Club Slides: Factors Associated With Response Time to Physiologic Monitor Alarms Bonafide CP, Localio AR, Holmes JH, et al. Video.
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Josep M. Llovet  Clinical Gastroenterology and Hepatology 
Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples from Japan. Serum LAMC2 levels in pancreatic adenocarcinoma (PDAC) and other samples.
Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.
Receiver under the operator characteristic (ROC) curve for the test accuracy of the final risk score in the entire external validation sample (c statistic=0.84,
Clinically significant precounseling cancer distress modifies counseling method's effect on testing uptake. *, statistically significant difference observed.
Flow chart of search strategy
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Risk of PTC associated with serum concentrations of TSH and thyroid hormones among females, stratified by tumor size. *, Conditional logistic regression,
Serum markers detect the presence of liver fibrosis: A cohort study
Introduction to epidemiology
T. Tzellos1,2; H. Yang3; F. Mu3; B. Calimlim4; J. Signorovitch3
Increased levels of branching on serum glycoproteins from patients with HCC. A, focus on larger branched glycans from 4 representative cirrhotics, and.
ROC curves showing the performance of the Diabetes Risk Score in predicting diabetes in the 1987 and 1992 cohorts; follow-up of both cohorts continued.
Presentation transcript:

39 DEVELOPED HCC by EASL criteria The use of an external QR Code is strictly forbidden The GALAD model as a tool for HCC surveillance: a re-analysis of a prospective study Philip J. Johnson1, Emily de Groot2, Hiroyuki Yamada3, Sarah Berhane1 1. Molecular & Clinical Cancer Medicine, University of Liverpool, & Clatterbridge Cancer Centre, Liverpool, United Kingdom. 2. University of St. Andrews, St. Andrews, United Kingdom. 3. Wako Life Sciences, Inc., Mountain View, CA, United States INTRODUCTION PATIENTS & METHODS 2 CONCLUSION The serum-based tool (“GALAD”), for HCC diagnosis, is based on Gender, Age and 3 serological biomarkers, AFP, AFP-L3 and DCP1. The model was based on rigorous statistical analysis of a prospectively collected cohort. It performs well irrespective of aetiology and tumour size (AUROC typically .85 - .95) and has been extensively and internationally validated in more than 6000 patients2. A prospective evaluation would support the model for use in clinical practice. Between 2000 and 2004, before GALAD was developed, a prospective study of these three biomarkers was undertaken in North America but they were considered independently, not in a combinatory model such as GALAD3. The GALAD score is validated in the US setting. The GALAD score is already significantly raised among those destined to develop HCC at the start of the study, when there is no radiological evidence of HCC and rises steadily thereafter. The GALAD score may offer an approach to risk stratification in the HCC surveillance setting. Limitations This study was not specifically designed to prospectively evaluate the GALAD score The GALAD score was built on established HCC cases, a separate model may be needed for ‘pre-radiographic diagnosis’. To visualize changes in biomarker levels over time (in observations taken at irregular time-points), we fitted a curve for each patient using fractional polynomial (FP) regression with GALAD, (or other variable of interest) as the dependent variable and “time to HCC diagnosis/last sample” as the explanatory variable. This allows values at various time points, up to two years prior to HCC diagnosis, to be interpolated and an aggregate curve thereby generated by calculating median value for all patients at that time point. 95% confidence intervals were generated by the bootstrap method. Table 1: Baseline characteristics of the patients in each group (same groups as those underlined and in italics and yellow from the flow chart) Variable No HCC (n=330) Developed HCCs (n=39) Established HCCs (n=54) Overall (n=423) Gender (% male) 71.87, n=327 79.49, n=39 88.68, n=53 74.70, n=419 Age (years) 52 (47, 55), n=326 53 (49, 56), n=39 55 (51, 62), n=53 52 (48, 57), n=418 AFP (ng/ml) 5.8 (3.4, 12.3), n=328 13.2 (7.9, 37.3), n=39 35.9 (7.4, 217.2), n=54 6.9 (3.7, 19.4), n=421 L3 (%) 6.9 (0.5, 9.2), n=328 10.9 (7.3, 19.7), n=39 8.75 (4.6, 16.2), n=54 7.3 (0.5, 9.7), n=421 DCP (ng/ml) 0.44 (0.23, 1.12), n=329 2.17 (0.43, 6.87), n=36 5.93 (1.69, 18.19), n=51 0.54 (0.27, 2.75), n=416 GALAD -2.38 (-3.53, -0.84), n=323 -0.44 (-1.37, 0.92), n=36 1.69 (-0.60, 4.06), n=50 -1.75 (-3.19, -0.20), n=409 Median (and interquartile range) presented for continuous variables. Percentages for categorical variables. RESULTS Taking the entire group of HCCs from the study (established HCC and developed HCC) the AUROC of the GALAD score was 0.86, significantly higher than the conventional marker of AFP (AUROC=0.79), p<0.01) (Figure 1). On entry into the study, the GALAD score among those destined to develop HCC was already higher than those not developing HCC, median of -0.44 vs -2.38 (Table 1) and AUROC of 0.79 (Figure 2). It rose steadily thereafter until diagnosis whereas the no HCC group remained low and did not change significantly (Figure 3). The figures for positive and negative predictive values suggests that using the cut-off of -0.63, surveillance can be risk stratified. Those above -0.63 having a 2 year risk of HCC of >20%, those below, 5% (Table 2). AIM ACKNOWLEDGEMENTS To re-analyse a North American HCC surveillance dataset, and thereby: Validate the GALAD model in a North American series. Examine the extent to which the application of the GALAD model may permit detection of HCC prior to its detection within a conventional radiologically based surveillance program. The authors wish to acknowledge the work of Sterling et al3 in terms of study design and data collection. REFERENCES 1.Johnson et al, Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):144-53 2.Berhane et al., Clinical Gastroenterology and Hepatology 2016;14:875–886 3.Sterling RK et al., Clinical Gastroenterology and Hepatology 2009;7:104 –113 PATIENTS & METHODS 1 369 without HCC Followed prospectively up to 2 years 39 DEVELOPED HCC by EASL criteria (4.3% p.a.) Biomarkers every 3-6 months, Imaging 6-12 months 54 ESTABLISHED HCC 330 NO-HCC 423 Enrolled HCV, cirrhotic Log-rank tests: GALAD vs AFP, p=0.0039 GALAD vs AFP-L3, p=0.0001 GALAD vs DCP, p=0.0089 Flow chart3 DISCLOSURES Philip Johnson received an educational grant from Wako Life Sciences, Inc. Figure 1: ROC curves comparing all HCCs vs no-HCC at diagnosis. Receiver operating characteristic (ROC) curve were plotted to assess GALAD discrimination between the non-HCCs and all HCCs at diagnosis, and between non-HCCs and HCC developers at first and last observation. Sensitivity, specificity, positive and negative predictive value for HCC development after passing GALAD cut-off of -0.63 (based on previous publication1) within one and two years were calculated. Figure 3: Serial changes in GALAD score, those developing HCC vs those not developing HCC CONTACT INFORMATION Table 2: Prediction of HCC development/detection within 1 and 2 years after crossing the GALAD boundary Cut-off Estimates For HCC detection within 1 years For HCC detection within 2 years -0.63 Sensitivity (95% Ci) 0.59 (0.39, 0.76) 0.69 (0.52, 0.82) Specificity (95% Ci) 0.71 (0.66, 0.76) 0.73 (0.68, 0.78) Positive Predictive Value (95% Ci) 0.15 (0.09, 0.23) 0.23 (0.16, 0.32) Negative Predictive Value (95% Ci) 0.95 (0.92, 0.97) Correspondence to: Philip Johnson Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK E-mail: philip.johnson@liverpool.ac.uk Figure 2: ROC curves comparing HCC developers and non-HCCs at baseline (first) and diagnosis (last) for GALAD.